After grabbing 0.72 million shares, the institutional investor is now in possession of 0.72 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 3.67% having worth around $1.06 million. Moreover, Citadel Securities LLC increased its share by 40050.0 to have a control over 55779.0 shares. And Gagnon Securities LLC raised its holdings to 47965.0 shares by acquiring 47965.0 shares or 0.24% of the stake.
Redhill Biopharma Ltd. ADR (RDHL) concluded trading on Wednesday at a closing price of $1.08, with 10.45 million shares of worth about $11.29 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -16.92% during that period and On Wednesday, January 24 the price saw a gain of about 21.15%. Currently the company’s common shares owned by public are about 19.67M shares, out of which, 19.58M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Fidelity Nasdaq Composite Index F, Yorkville Health Care Opportuniti, and Kivun 2B 70/30 IL are the top 3 mutual funds which are holding stakes in Redhill Biopharma Ltd. ADR Fidelity Nasdaq Composite Index F is currently holding 1040.0 shares of worth totaling $1518.0. The company recently came buying 0.0 shares which brought its stake up to 0.01% of the company’s outstanding shares. Yorkville Health Care Opportuniti sold 1.0 shares, after which its hold over company’s outstanding shares shrunk to 0.00%, leaving 359.0 shares with the mutual fund that have a worth of about $524.0. Kivun 2B 70/30 IL, after buying 187.0 shares, have now control over 0.00% of the stake in the company. It holds 0.0 shares of worth $273.0.
However, the stock later moved at a day high price of 1.2601, or with a gain of 21.15%. Stock saw a price change of 3.85% in past 5 days and over the past one month there was a price change of -15.62%. Year-to-date (YTD), RDHL shares are showing a performance of -26.03% which decreased to -84.21% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.26 but also hit the highest price of $11.50 during that period. The average intraday trading volume for Redhill Biopharma Ltd. ADR shares is 9.22 million. The stock is currently trading -13.18% below its 20-day simple moving average (SMA20), while that difference is down -5.43% for SMA50 and it goes to -19.12% lower than SMA200.
Armistice Capital LLC acquired 0.72 million shares of Redhill Biopharma Ltd. ADR having value of about $1.06 million. Redhill Biopharma Ltd. ADR (NASDAQ: RDHL) currently have 19.67M outstanding shares and institutions hold larger chunk of about 4.55% of that. Holding of mutual funds in the company is about 0.01% while other institutional holders and individual stake holders have control over 4.54% and — of the stake respectively.
The stock has a current market capitalization of $21.24M and its 3Y-monthly beta is at 3.46. It has posted earnings per share of -$3.16 in the same period. It has Quick Ratio of 0.78 while making debt-to-equity ratio of 0.66. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RDHL, volatility over the week remained 14.17% while standing at 12.37% over the month.
Analysts are in expectations that Redhill Biopharma Ltd. ADR (RDHL) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is $0 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.5 in the same quarter a year ago.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Cantor Fitzgerald on August 31, 2021 offering an Overweight rating for the stock and assigned a target price of $22 to it.
